Literature DB >> 3872187

Two monoclonal antibodies raised against a Burkitt lymphoma cell line recognise different cell types within lymphoid follicles.

L J Murray, S Dhut, L C Walker, M Rainey, J A Habeshaw.   

Abstract

Monoclonal antibodies were raised against a laboratory derived variant of the Raji Burkitt lymphoma cell line. We have characterized two of these antibodies by screening on haematopoietic cell lines, and frozen sections of both reactive and neoplastic lymphoid tissue, and found reactivity with separate cellular components of lymphoid follicles. Monoclonal FW37.4.D5 reacts in section specifically with follicular dendritic reticular cells. Monoclonal 35.1C5 reacts with a subpopulation of splenic marginal zone, and lymph node mantle zone, B lymphocytes, but stains only rare cells within germinal centres. This monoclonal is operationally B lymphocyte specific, distinguishing an 'intermediate' B cell subset, represented in lymphoma by B chronic lymphocytic leukaemia, B hairy cell leukaemia and centrocytic lymphoma.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3872187      PMCID: PMC1577118     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  30 in total

1.  A new mouse myeloma cell line that has lost immunoglobulin expression but permits the construction of antibody-secreting hybrid cell lines.

Authors:  J F Kearney; A Radbruch; B Liesegang; K Rajewsky
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

2.  ANTIGENS IN IMMUNITY. IV. CELLULAR LOCALIZATION OF 125-I- AND 131-I-LABELLED FLAGELLA IN LYMPH NODES.

Authors:  G J NOSSAL; G L ADA; C M AUSTIN
Journal:  Aust J Exp Biol Med Sci       Date:  1964-06

3.  Germinal centres and the origin of the B-cell system. I. Germinal centres in the rabbit appendix.

Authors:  P Nieuwenhuis; C E van Nouhuijs; J H Eggens; F J Keuning
Journal:  Immunology       Date:  1974-03       Impact factor: 7.397

4.  The biochemical characterization of a cell surface antigen associated with acute lymphoblastic leukemia and lymphocyte precursors.

Authors:  R A Newman; R Sutherland; M F Greaves
Journal:  J Immunol       Date:  1981-05       Impact factor: 5.422

5.  Activation of mouse complement by different classes of mouse antibody.

Authors:  G G Klaus; M B Pepys; K Kitajima; B A Askonas
Journal:  Immunology       Date:  1979-12       Impact factor: 7.397

6.  Antibodies to major histocompatibility antigens produced by hybrid cell lines.

Authors:  G Galfre; S C Howe; C Milstein; G W Butcher; J C Howard
Journal:  Nature       Date:  1977-04-07       Impact factor: 49.962

7.  A monoclonal antibody (BA-1) reactive with cells of human B lymphocyte lineage.

Authors:  C S Abramson; J H Kersey; T W LeBien
Journal:  J Immunol       Date:  1981-01       Impact factor: 5.422

8.  Monoclonal antibody to human fibronectin: production and characterization using human muscle cultures.

Authors:  F S Walsh; S E Moore; S Dhut
Journal:  Dev Biol       Date:  1981-05       Impact factor: 3.582

9.  A monoclonal antibody to human acute lymphoblastic leukaemia antigen.

Authors:  J Ritz; J M Pesando; J Notis-McConarty; H Lazarus; S F Schlossman
Journal:  Nature       Date:  1980-02-07       Impact factor: 49.962

10.  A monoclonal antibody identifying a cell surface antigen shared by common acute lymphoblastic leukemias and B lineage cells.

Authors:  M F Greaves; W Verbi; J Kemshead; R Kennett
Journal:  Blood       Date:  1980-12       Impact factor: 22.113

View more
  2 in total

1.  Search for the critical characteristics of phenotypically different B cell lines, Burkitt lymphoma cells and lymphoblastoid cell lines, which determine differences in their functional interaction with allogeneic lymphocytes.

Authors:  J Avila-Cariño; S Torsteinsdottir; B Ehlin-Henriksson; M G Masucci; E Klein
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

2.  Human follicular dendritic cells (FDC): a study with monoclonal antibodies (MoAb).

Authors:  G D Johnson; D L Hardie; N R Ling; I C Maclennan
Journal:  Clin Exp Immunol       Date:  1986-04       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.